A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India.
Diabetes Metab Syndr
; 15(1): 407-413, 2021.
Article
in English
| MEDLINE | ID: covidwho-1062312
ABSTRACT
BACKGROUND AND AIMS:
Diabetes and coronavirus disease 2019 (COVID-19) share a bidirectional relationship. Hyperglycemia occurring in the setting of either previously diagnosed or undiagnosed diabetes is known to be associated with poor outcomes. Here, we aim to provide a simple and practical guidance on the diagnosis and management of hyperglycemia in admitted patients with COVID-19.METHODS:
The guidance is formulated based on experience of authors and relevant literature on the subject searched using Pubmed.RESULTS:
Every patient admitted to a COVID care facility should be investigated for hyperglycemia using a combination of tests including capillary blood glucose, fasting plasma glucose and HbA1c. Oral glucose lowering drugs can be considered in patients with mild COVID illness who have mild hyperglycemia [pre-meal blood glucose of <180 mg/dl (10 mmol/L) and post-meal blood glucose of <250 mg/dl (13.9 mmol/L)] and no contraindication to the use of these agents.. All patients with moderate-severe disease and/or hyperglycemia of greater severity should be initiated on insulin therapy. Hyperglycemia should be aggressively screened for and managed in patients receiving systemic glucocorticoids.CONCLUSION:
This document provides a broad overview on the diagnosis and management of hyperglycemia at COVID care facilities and should be useful to a wide range of healthcare personnel involved in care of patients with COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mass Screening
/
COVID-19
/
Hospitalization
/
Hyperglycemia
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
/
Reviews
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS